Deciphera’s Qinlock Hits GIST Roadblock With Phase III Failure

Deciphera Pharmaceuticals, Inc.’s Qinlock (ripretinib) is stuck in the later lines of gastrointestinal stromal tumor (GIST) treatment for the foreseeable future following the failure of a Phase III trial to bring it into earlier lines, while the biotech itself looks set to enter a lull for a while in terms of pipeline catalysts.

The company announced topline results on 5 November from the 453-patient Phase III INTRIGUE study comparing Qinlock against Pfizer Inc.’s Sutent (sunitinib) in second-line GIST patients who had previously received imatinib